{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T19:28:58Z","timestamp":1769282938646,"version":"3.49.0"},"reference-count":24,"publisher":"Japanese Urological Association","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. j. urol"],"published-print":{"date-parts":[[2025,1,20]]},"DOI":"10.5980\/jpnjurol.116.10","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T22:07:47Z","timestamp":1768860467000},"page":"10-16","source":"Crossref","is-referenced-by-count":0,"title":["CLINICAL OUTCOMES OF NEUROENDOCRINE CARCINOMA OF THE URINARY BLADDER","\u8180\u80f1\u795e\u7d4c\u5185\u5206\u6ccc\u764c\u306b\u5bfe\u3059\u308b\u81e8\u5e8a\u7684\u691c\u8a0e"],"prefix":"10.5980","volume":"116","author":[{"given":"Keisuke","family":"Kuretake","sequence":"first","affiliation":[{"name":"Department of Urology, University of Occupational and Environmental Health"},{"name":"Department of Urology, Shinyukuhashi Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinori","family":"Minato","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Occupational and Environmental Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Urology, Shinyukuhashi Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Kurate Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4001","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1) Cheng L, Pan CX, Yang XJ, Beltran AL, MacLennan GT, Lin H, Kuzel TM, Papavero V, Tretiakova M, Nigro K, Koch MO and Eble JN: Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer., 101, 957-962, 2004.","DOI":"10.1002\/cncr.20456"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2) Cramer SF, Akikawa M and Cebelin M: Neurosecretory granules in small cell invasive carcinoma of the urinary bladder. Cancer., 47, 724-730, 1981.","DOI":"10.1002\/1097-0142(19810215)47:4<724::AID-CNCR2820470417>3.0.CO;2-2"},{"key":"3","unstructured":"3) Abenoza P, Manivel C and Sibley RK: Adenocarcinoma with neuroendocrine differentiation of the urinary bladder. Arch Pathol Lab Med., 110, 1062-1066, 1986."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Abdel-Rahman O: Validation of the eighth AJCC new substages for bladder cancer among different staging contexts. Clin Genitourin Cancer., 15, e1095-e1106, 2017.","DOI":"10.1016\/j.clgc.2017.07.025"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45 (2), 228-247, 2009 doi: 10.1016\/j.ejca.2008.10.026.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Kanda Y: Investigation of the freely available easy-to-use software  &apos;EZR&apos;  for medical statistics. Bone Marrow Transplant, 48 (3), 452-458, 2013 doi: 10.1038\/bmt.2012.244.","DOI":"10.1038\/bmt.2012.244"},{"key":"7","unstructured":"7) George JN, Mahul BA, Daniel MB, Eva MC, Anthony JG, Arndt H, Santosh M, Maria RR, Mark AR, John RS, Puay HT, Satish KT, Toyonori T, Samra T, Ian C and Holger M: The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors. Eur Urol., 82, 469-482, 2022."},{"key":"8","unstructured":"8) \u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u7de8: \u814e\u76c2\u30fb\u5c3f\u7ba1\u30fb\u8180\u80f1\u764c\u53d6\u6271\u3044\u898f\u7d04. \u7b2c2\u7248, p 46-49, \u533b\u5b66\u56f3\u66f8\u51fa\u7248, \u6771\u4eac, 2021."},{"key":"9","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/1097-0142(19890915)64:6<1347::AID-CNCR2820640629>3.0.CO;2-Q","volume":"64","author":"CE Blomjous","year":"1995","unstructured":"9) Blomjous CE, Vos W, Voogt HJD, Valk PV and Meijer CJ: Small cell carcinoma of the urinary bladder. Cancer., 64, 1347-1357, 1995.","journal-title":"Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0008-543X","issn-type":"print"},{"key":"10","unstructured":"10) \u9152\u8c37 \u5fb9, \u6e05\u6c34\u6d0b\u7950, \u6749\u91ce\u5584\u96c4, \u5c71\u5d0e\u4fca\u6210, \u4eca\u6751\u6b63\u660e, \u677e\u4e95\u559c\u4e4b, \u4e95\u4e0a\u8cb4\u535a, \u5927\u4e45\u4fdd\u548c\u4fca, \u795e\u6ce2\u5927\u5df1, \u5409\u6751\u8015\u6cbb, \u5c0f\u5ddd \u4fee: \u8180\u80f1\u539f\u767a\u5c0f\u7d30\u80de\u764c\u306e\u81e8\u5e8a\u7684\u691c\u8a0e. \u6ccc\u5c3f\u7d00\u8981, 60, 221-225, 2014."},{"key":"11","unstructured":"11) \u5c71\u7530\u7fd4\u5927, \u677e\u5c3e\u670b\u535a, \u524d\u5ddd\u66a2\u79c0, \u571f\u5c71\u5f69\u83ef, \u4e2d\u6751\u88d5\u4e00\u90ce, \u4e2d\u897f\u88d5\u7f8e, \u5b89\u7530\u62d3\u53f8, \u5149\u6210\u5065\u8f14, \u5927\u5ead\u5eb7\u53f8\u90ce, \u671b\u6708\u4fdd\u5fd7, \u4eca\u6751\u4eae\u4e00: \u8180\u80f1\u539f\u767a\u5c0f\u7d30\u80de\u764c\u306e1\u4f8b. \u897f\u65e5\u6ccc\u5c3f, 86, 250-254, 2024."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Dursun F, Elshabrawy A, Wnag H, Wu S, Liss MA, Kaushik D, Grosser D, Svastek RS and Mansour AM: Histological variants of non-muscle invasive bladder cancer: Survival outcomes of radical cystectomy vs. bladder preservation therapy. Urol Oncol., 40, 275.e1-275.e10, 2022.","DOI":"10.1016\/j.urolonc.2022.02.004"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J, Groshen S, Stein JP and Skinner DG: Radical cystectomy for primary neuroendocrine tumors of the bladder: The University of Southern California experience. J Urol., 174, 93-96, 2005.","DOI":"10.1097\/01.ju.0000162085.20043.1f"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Teo MY, Guercio BJ, Arora A, Hao X, Regazzi AM, Donahue T, Herr HW, Goh AC, Cha EK, Pietzak E, Donat SM, Dalbagni G, Bochner BH, Olgac S, Sarungbam J, Sirintrapun SJ, Chen YB, Gopalan A, Fine SW, Tickoo SK, Reuter VE, Weigelt B, Schultheis AM, Funt SA, Bajorin DF, Solit DB, Iyer G, Ostrovnaya I, Rosenberg JE and Ahmadie HA: Long-Term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated with Neoadjuvant Chemotherapy. Clin Genitourin Cancer., 20, 431-441, 2022.","DOI":"10.1016\/j.clgc.2022.05.005"},{"key":"15","unstructured":"15) \u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u7de8: \u8180\u80f1\u764c\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3. 2019\u5e74\u7248, p 139-140, \u533b\u5b66\u56f3\u66f8\u51fa\u7248, \u6771\u4eac, 2019."},{"key":"16","unstructured":"16) NCCN Guidelines: Bladder Cancer Version 4.2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf (cited 2024-8-23)."},{"key":"17","doi-asserted-by":"publisher","unstructured":"17) Vetterlein MW, Wankowicz SA, Seisen T, Lander R, Loppenberg B, Chun FKH, Menon M, Sun M, Barletta JA, Choueiri TK, Bellmunt J, Trinh QD and Preston MA: Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer., 123, 4346-4355, 2017.","DOI":"10.1002\/cncr.30907"},{"key":"18","unstructured":"18) EAU Guidelines: Muscle-invasive and Metastatic Bladder Cancer. https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer (cited 2024-8-23)."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Minato A, Murooka K, Okumura Y, Takaba T, Higashijima K, Nagata Y, Tomisaki I, Harada K and Fujimoto N: Efficacy of platinum-based chemotherapy in patients with metastatic urothelial carcinoma with variant histology. in vivo., 38, 873-880, 2024.","DOI":"10.21873\/invivo.13513"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, Grossman HB, Swanson DA and Millikan RE: Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J. Urol., 172 (2), 481-484, 2004.","DOI":"10.1097\/01.ju.0000132413.85866.fc"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kl\u00fcmper N, Ralser DJ, Ellinger J, Roghmann F, Albrecht J, Below E, Alajati A, Sikic D, Breyer J, Bolenz C, Zengerling F, Erben P, Schwamborn K, Wirtz RM, Horn T, Nagy D, Toma M, Kristiansen G, B\u00fcttner T, Hahn O, Gr\u00fcwald V, Darr C, Erne E, Rausch S, Bedke J, Schlack K, Abbas M, Zsch\u00e4bitz S, Schwab C, Mustea A, Adam P, Manseck A, Wullich B, Ritter M, Hartmann A, Gschwend J, Weichert W, Erlmeier F, H\u00f6lzel M and Eckstein M: Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance. Clin Cancer Res., 29, 1496-1505, 2023.","DOI":"10.1158\/1078-0432.CCR-22-1764"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Ghali F, Vakar-Lopez F, Roudier MP, Garcia J, Arora S, Cheng HH, Schweizer MT, Haffner MC, Lee JK, Yu EY, Grivas P, Montgomery B, Hsieh AC, Wright JL and Lam HM: Metastatic bladder cancer expression and subcellular localization of Nectin-4 and Trop-2 in variant histology: A rapid autopsy study. Clin Genitourin Cancer., 21, 669-678, 2023.","DOI":"10.1016\/j.clgc.2023.05.014"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Minato A, Furubayashi M, Nagata Y, Tomoda T, Masaoka T, Song Y, Hori Y, Kiyoshima K, Negishi T, Kuroiwa K, Seki N, Tomisaki I, Harada K, Nakamura M and Fujimoto N: Prognostic impact of histologic subtype and divergent differentiation in patients with metastatic urothelial carcinoma treated with enfortumab vedotin: a multicenter retrospective study. Curr Oncol., 31, 862-871, 2024.","DOI":"10.3390\/curroncol31020064"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Akamatsu H, Nakamura K, Ebara T, Inaba K, Itasaka S, Jingu K, Kosaka Y, Murai T, Nagata K, Soejima T, Takahashi S, Toyoda T, Toyoshima S, Nemoto K and Akimoto T: Organ-preserving approach via radiotherapy for small cell carcinoma of the bladder: an analysis based on the Japanese Radiation Oncology Study Group (JROSG) survey. J Radiat Res., 60, 509-516, 2019.","DOI":"10.1093\/jrr\/rrz018"}],"container-title":["The Japanese Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/116\/1\/116_10\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T04:31:01Z","timestamp":1769229061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/116\/1\/116_10\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5980\/jpnjurol.116.10","relation":{},"ISSN":["0021-5287","1884-7110"],"issn-type":[{"value":"0021-5287","type":"print"},{"value":"1884-7110","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]}}}